The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models.

Sanz-Álvarez, Marta; Martín-Aparicio, Ester; Luque, Melani; Zazo, Sandra; Martínez-Useros, Javier; Eroles, Pilar; Rovira, Ana; Albanell, Joan; Madoz-Gúrpide, Juan; Rojo, Federico.

Afiliação

Sanz-Álvarez M; Department of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, 28040 Madrid, Spain.
Martín-Aparicio E; Department of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, 28040 Madrid, Spain.
Luque M; Department of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, 28040 Madrid, Spain.
Zazo S; Department of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, 28040 Madrid, Spain.
Martínez-Useros J; Translational Oncology Division, OncoHealth Institute, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), 28040 Madrid, Spain.
Eroles P; Institute of Health Research INCLIVA-CIBERONC, 46010 Valencia, Spain.
Rovira A; Department of Physiology, University of Valencia, 46010 Valencia, Spain.
Albanell J; Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain.
Madoz-Gúrpide J; Medical Oncology Department, Hospital del Mar-CIBERONC, 08003 Barcelona, Spain.
Rojo F; Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain.